Crewe Advisors LLC Has $775,000 Stake in Merck & Co., Inc. $MRK

Crewe Advisors LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 2.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,790 shares of the company’s stock after selling 231 shares during the period. Crewe Advisors LLC’s holdings in Merck & Co., Inc. were worth $775,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Peoples Financial Services CORP. boosted its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock worth $1,803,000 after buying an additional 122 shares during the period. McLean Asset Management Corp lifted its holdings in shares of Merck & Co., Inc. by 3.7% during the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock worth $292,000 after purchasing an additional 125 shares during the period. Cora Capital Advisors LLC grew its stake in shares of Merck & Co., Inc. by 2.4% in the second quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock worth $423,000 after purchasing an additional 125 shares during the last quarter. Foundation Wealth Management LLC PA grew its stake in shares of Merck & Co., Inc. by 2.4% in the first quarter. Foundation Wealth Management LLC PA now owns 5,361 shares of the company’s stock worth $481,000 after purchasing an additional 127 shares during the last quarter. Finally, Saiph Capital LLC increased its holdings in Merck & Co., Inc. by 3.7% in the first quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock valued at $320,000 after purchasing an additional 128 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $84.78 on Monday. The company has a market cap of $211.76 billion, a price-to-earnings ratio of 13.06, a price-to-earnings-growth ratio of 0.93 and a beta of 0.37. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $109.92. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average of $83.91 and a 200-day moving average of $81.31.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion for the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th were paid a $0.81 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 49.92%.

Analyst Upgrades and Downgrades

Several research analysts have commented on MRK shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their target price for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company lowered their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. Morgan Stanley reduced their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Finally, Citigroup began coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They set a “neutral” rating and a $95.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $104.33.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.